Diabetes Mellitus News and Research RSS Feed - Diabetes Mellitus News and Research

Diabetes mellitus is a severe and debilitating chronic disease that develops in nearly 5 percent of the world’s population. People with this disease have a shortage of insulin or a reduced ability to use insulin, the hormone regulating blood glucose levels, which is normally produced by the pancreas. In the United States alone, an estimated 18 million people have diabetes, and each year about 1 million Americans are diagnosed with the disease. It is the sixth leading cause of death in the US and is responsible for over 200,000 deaths a year. Insulin-dependent (type I) diabetes accounts for around 10% of diabetics. For those patients, suffering from an inability of their pancreas to produce insulin, the only practical treatment possible is regular insulin replacement by multiple daily injections. Transplantation of a pancreas or pancreatic tissue would be beneficial to millions of such patients in that it would restore their normal ability to produce self insulin. Transplantation of human pancreas or pancreatic islets is a practiced and time-honored such therapeutic approach, but is extremely limited by the severe shortage of human donor organs. Tissera's R&D efforts in this domain are directed towards the development of a universally available and reliable source of animal fetal donor pancreatic precursor tissue, suitable for transplantation and eventual normal structural and functional growth in human diabetics.
Resverlogix, Emerald Logic complete collaborative research program

Resverlogix, Emerald Logic complete collaborative research program

Resverlogix Corp. today announced that it has completed a collaborative research program with Emerald Logic, a leader in quantitative analytics. Using Fast Collective Evolution Technology (FACET), Emerald Logic analyzed Resverlogix's complete clinical dataset including all measurements obtained from each of 798 patients who participated in the Company's Phase 2 clinical trials ASSERT, SUSTAIN and ASSURE. [More]
Sanofi announces FDA approval of Toujeo insulin to improve glycemic control in people with diabetes

Sanofi announces FDA approval of Toujeo insulin to improve glycemic control in people with diabetes

Sanofi announced today that the U.S. Food and Drug Administration approved Toujeo (insulin glargine [rDNA origin] injection, 300 U/mL), a once-daily long-acting basal insulin, to improve glycemic control in adults living with type 1 and type 2 diabetes. Toujeo is expected to be available in the U.S. at the beginning of Q2 2015. [More]
Tandem Diabetes Care announces release of t:simulator App

Tandem Diabetes Care announces release of t:simulator App

Tandem Diabetes Care, Inc., a medical device company and manufacturer of the t:slim and t:flex Insulin Pumps, today announced the release of the t:simulator App, which mimics the touchscreen interface and features of the t:slim Insulin Pump. [More]
Study: Definitive indicator of diabetes control deceptively high in African-American children

Study: Definitive indicator of diabetes control deceptively high in African-American children

A new study confirms the findings of two earlier LSU Health New Orleans studies that the definitive indicator of diabetes control, the HbA1c, is deceptively high in African-American children. [More]
Study shows amyloid formation may link type 2 diabetes and Alzheimer disease

Study shows amyloid formation may link type 2 diabetes and Alzheimer disease

The pathological process amyloidosis, in which misfolded proteins (amyloids) form insoluble fibril deposits, occurs in many diseases, including Alzheimer disease (AD) and type 2 diabetes mellitus (T2D). [More]
Blood pressure-lowering treatment lowers CVD, heart disease risks among type 2 diabetes patients

Blood pressure-lowering treatment lowers CVD, heart disease risks among type 2 diabetes patients

Blood pressure-lowering treatment among patients with type 2 diabetes is associated with a lower risk of cardiovascular disease (CVD) and heart disease events and improved mortality, according to a study in the February 10 issue of JAMA. [More]
PE/GHTN linked to higher frequency of cardiovascular and metabolic abnormalities

PE/GHTN linked to higher frequency of cardiovascular and metabolic abnormalities

In a study to be presented on Feb. 5 in an oral concurrent session at 2:45 p.m. PST, at the Society for Maternal-Fetal Medicine's annual meeting, The Pregnancy Meeting™, in San Diego, researchers of the MFMU Network will present findings of long term cardiovascular and metabolic abnormalities five to ten years later in women with preeclampsia/gestational hypertension during pregnancy. [More]
Study looks at effect of probiotic capsule intervention on metabolic health among women with GDM

Study looks at effect of probiotic capsule intervention on metabolic health among women with GDM

In a study to be presented on Feb. 5 in an oral concurrent session at 1:15 p.m. PST, at the Society for Maternal-Fetal Medicine's annual meeting, The Pregnancy Meeting, in San Diego, researchers will report on the effect of a probiotic capsule intervention on maternal metabolic parameters and pregnancy outcomes among women with gestational diabetes. [More]
Researchers to highlight impact of maternal glycemia on childhood obesity at The Pregnancy Meeting

Researchers to highlight impact of maternal glycemia on childhood obesity at The Pregnancy Meeting

In a study to be presented on Feb. 5 in an oral concurrent session at 1:15 p.m. PST, at the Society for Maternal-Fetal Medicine's annual meeting, The Pregnancy Meeting, in San Diego, researchers will report on the impact of maternal glycemia on childhood obesity and metabolic dysfunction. [More]
Immunomic Therapeutics, Astellas Pharma sign license deal to develop LAMP-vax DNA vaccines

Immunomic Therapeutics, Astellas Pharma sign license deal to develop LAMP-vax DNA vaccines

Immunomic Therapeutics, Inc. ("Immunomic Therapeutics"), a company developing next-generation vaccines based on the LAMP-vax platform, and Astellas Pharma Inc. ("Astellas") today announced they have entered into an exclusive license agreement for Japan to develop and commercialize JRC2-LAMP-vax, Immunomic Therapeutics' vaccine designed to treat allergies induced by Japanese red cedar pollen. [More]
Umbilical cord-derived stem cells from women with gestational diabetes show premature aging

Umbilical cord-derived stem cells from women with gestational diabetes show premature aging

Multipotent cells isolated from the human umbilical cord, called mesenchymal stromal cells (hUC-MSCs) have shown promise for use in cell therapy to treat a variety of human diseases. However, intriguing new evidence shows that hUC-MSCs isolated from women with gestational diabetes demonstrate premature aging, poorer cell growth, and altered metabolic function, as reported in an article in Stem Cells and Development, a peer-reviewed journal from Mary Ann Liebert, Inc., publishers. [More]
Tandem Diabetes Care receives FDA clearance to market t:flex Insulin Pump

Tandem Diabetes Care receives FDA clearance to market t:flex Insulin Pump

Tandem Diabetes Care, Inc., a medical device company and manufacturer of the t:slim Insulin Pump, today announced that the U.S. Food and Drug Administration has granted the Company clearance to market the t:flex Insulin Pump. At 480 units, the insulin reservoir of the t:flex Pump has the largest capacity currently available in the United States. [More]
FDA approves Novo Nordisk’s weight loss injection, Saxenda

FDA approves Novo Nordisk’s weight loss injection, Saxenda

Novo Nordisk today announced that the Food and Drug Administration (FDA) has approved the new drug application (NDA) for Saxenda® (liraglutide [rDNA origin] injection), the first once-daily glucagon-like peptide-1 (GLP-1) receptor agonist for chronic weight management. [More]
Novartis announces FDA approval of Signifor LAR for treatment of patients with acromegaly

Novartis announces FDA approval of Signifor LAR for treatment of patients with acromegaly

Novartis announced today that the US Food and Drug Administration has approved Signifor long-acting release (LAR) (pasireotide) for injectable suspension, for intramuscular use, for the treatment of patients with acromegaly who have had an inadequate response to surgery and/or for whom surgery is not an option. [More]
TWi Biotechnology gets approval of Phase II clinical trial protocol for AC-201 CR tablets

TWi Biotechnology gets approval of Phase II clinical trial protocol for AC-201 CR tablets

TWi Pharmaceuticals, Inc. today announced that its fully owned subsidiary, TWi Biotechnology, Inc., has received US FDA and Taiwan FDA approval of a protocol for a Phase II clinical trial of its AC-201 controlled-release (CR) tablets for the indications of high blood uric acid level and gout. [More]
Triple hormone reduces body weight, improves insulin sensitivity

Triple hormone reduces body weight, improves insulin sensitivity

Recently, the researchers had constructed several single molecules with dual hormone action. Now, for the first time, the researchers succeeded in designing a substance that combines three metabolically active hormone components (GLP-1, GIP and glucagon) and offers unmatched potency to fight metabolic diseases in pre-clinical trials. [More]
Continuous glucose monitoring (CGM) mobile communications: an interview with Jorge Valdes

Continuous glucose monitoring (CGM) mobile communications: an interview with Jorge Valdes

Type 1 diabetes is a complex condition to manage. It requires continuous, around the clock monitoring of blood glucose levels, which change repeatedly throughout the day and night. [More]
Presence of certain proteins in HDL can lead to cardiovascular risk

Presence of certain proteins in HDL can lead to cardiovascular risk

A current study by the MedUni Vienna has shown that changes to the "good cholesterol" HDL (High-Density Lipoprotein) can be associated with cardiovascular diseases: by developing a new laboratory test, scientists at the Institute of Medical Genetics and the Department of Nephrology & Dialysis (University Department of Internal Medicine III) at the MedUni Vienna have demonstrated for the first time that the presence of certain proteins in the HDL can lead to an increased risk of cardiovascular disease and mortality. [More]
Preconception care can significantly lower adverse birth outcomes in diabetic women

Preconception care can significantly lower adverse birth outcomes in diabetic women

Pregnant women with diabetes are at an increased risk for many adverse birth outcomes. Preconception care (PCC) can significantly lower these risks by helping pregnant mothers with diabetes control their glucose levels, resulting in healthier babies and less money spent on complicated deliveries and lifelong medical complications. [More]
Five USF faculty members named AAAS Fellow

Five USF faculty members named AAAS Fellow

Five faculty members from the University of South Florida in Tampa have been named Fellows of the American Association for the Advancement of Science. Election as an AAAS Fellow is an honor bestowed upon AAAS members by their peers. [More]
Advertisement
Advertisement